RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target
Aardvark Therapeutics Inc AARD
$5.35
▲ +1.52%
(+$0.08)
⬆️ Above Yest. High
Open
$5.21
Prev Close
$5.27
Day Range
$5.00 – $5.39
52W Range
$3.35 – $17.94
Market Cap
$117.08M
Beta
3.62
EPS (TTM)
$-3.21
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2025-02-13 |
| Shares Out. | 21,880,000 |
| Website | aardvarktherapeutics.com/ ↗ |
| Phone | 18582257696 |
| Employees | 28 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$14.4M |
| Free Cash Flow | -$69.4M |
| Total Assets | $81.5M |
| Total Liabilities | $6.7M |
| Equity | $74.8M |
About Aardvark Therapeutics Inc
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Aardvark Therapeutics Inc is a publicly traded company under the ticker symbol AARD on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-09-01)